Ionis Pharmaceuticals IONS Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's other non-current liabilities?
- Ionis Pharmaceuticals (IONS) reported other non-current liabilities of $28.27M in Q1 2026.
- How has Ionis Pharmaceuticals's other non-current liabilities changed year-over-year?
- Ionis Pharmaceuticals's other non-current liabilities decreased by 49.2% year-over-year, from $55.67M to $28.27M.
- What is the long-term trend for Ionis Pharmaceuticals's other non-current liabilities?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's other non-current liabilities has grown at a 41.8% compound annual growth rate (CAGR), from $6.95M to $28.12M.
- What does other non-current liabilities mean?
- Miscellaneous long-term debts and obligations not categorized elsewhere.
- How do you interpret other non-current liabilities?
- Significant increases may warrant further investigation into the nature of the underlying long-term commitments.
- How does other non-current liabilities compare across companies?
- Standard line item in balance sheets across all sectors for reporting miscellaneous long-term debt.